SEX-SPECIFIC DIFFERENCES IN RESPONSE TO RUXOLITINIB VERSUS BEST AVAILABLE THERAPY IN PATIENTS WITH POLYCYTHEMIA VERA TREATED IN THE RANDOMIZED PHASE 2B RUXO-BEAT CLINICAL TRIAL

Authors
Category Primary study
Conference31st Congress of the European Hematology Association Congress, EHA 2026
Year 2026
This article has no abstract
Epistemonikos ID: 71f032507959b2949a5509e652b474be2dc4a35e
First added on: Aug 08, 2026